15 February 2017 EMA/COMP/870730/2016 Inspections, Human Medicines Pharmacovigilance and Committees Division

COMP work plan 2017 adopted by the Committee on 08 December 2016

Table of contents 1. Evaluation activities for human medicines .............................................. 2 1.1. Pre-authorisation activities .................................................................................... 2 1.1.1. Designation of orphan medicines ......................................................................... 2

2. Horizontal activities and other areas ....................................................... 5 2.1. Committees and Working Parties ............................................................................ 5 2.1.1. Additional objectives and activities....................................................................... 5 2.2. International activities .......................................................................................... 6 2.2.1. Exchange of information ..................................................................................... 6

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimil +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact

An agency of the European Union

© European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged.

1. Evaluation activities for human medicines 1.1. Pre-authorisation activities 1.1.1. Designation of orphan medicines Key objectives •

Implement changes introduced in the Commission Notice on the Application of Articles 3, 5 and 7 of Regulation (EC) No 141/2000 on Orphan Medicinal Products (2016/C 424/03).



Improve the quality of initial orphan designation applications by sharing COMP experience and issuing further recommendations



Ensure consistency of answers to questions on significant benefit in Protocol Assistance and clarify the requirements for the demonstration of significant benefit in order to improve chances of success at the time of Orphan Designation and Marketing Authorisation



Ensure consistency, transparency, quality and detail of the grounds of opinions given by the COMP on significant benefit at the time of marketing authorisation

Activities in 2017 •

Streamline processes in line with the Commission Notice (2016/C 424/03) −

Initial orphan designation



Maintenance



Type II variations

COMP topic leader: Lesley Greene Other Committee participants (members of the Significant Benefit Working Group): Member/Alternate

Name

Member State

Chair

Bruno Sepodes

Member

Brigitte Blöchl-Daum

AT

Member

Kateřina Kopečková

CZ

Member

Frauke Naumann-Winter

DE

Member

Jens Ersbøll

DK

Member

Vallo Tillmann

EE

Member

Armando Magrelli

IT

Member

Michel Hoffmann

LU

Member

Violeta Stoyanova

NL

Member

Bożenna Dembowska-Bagińska

PL

Member

Daniel O’Connor

UK

Member

Pauline Evers

Patients’ organisations

Member

Mario Ricciardi

representative Patients’ organisations representative Member

COMP work plan 2017 EMA/COMP/870730/2016

Kerstin Westermark

Nominated by EC

Page 2/6

Member/Alternate

Name

Member State

Member

Giuseppe Capovilla

Nominated by EC

Expert

Virginie Hivert

EURORDIS*

*Affiliation



Update “COMP recommendation on elements required to support the medical plausibility and the assumption of significant benefit for an orphan designation, EMEA/COMP/436/01” taking into account the Commission Notice (2016/C 424/03) and principles identified by the working group on significant benefit when assessing criteria for orphan designation (at designation and at marketing authorisation). COMP topic leader: Lesley Greene Other Committee participants (members of the Significant Benefit Working Group): Member/Alternate

Name

Member State

Chair

Bruno Sepodes

Member

Brigitte Blöchl-Daum

AT

Member

Kateřina Kopečková

CZ

Member

Frauke Naumann-Winter

DE

Member

Jens Ersbøll

DK

Member

Vallo Tillmann

EE

Member

Armando Magrelli

IT

Member

Michel Hoffmann

LU

Member

Violeta Stoyanova-Beninska

NL

Member

Bożenna Dembowska-Bagińska

PL

Member

Daniel O’Connor

UK

Member

Pauline Evers

Patients’ organisations

Member

Mario Ricciardi

representative Patients’ organisations representative Member

Kerstin Westermark

Nominated by EC

Member

Giuseppe Capovilla

Nominated by EC

Expert

Virginie Hivert

EURORDIS*

*Affiliation



Development of strategies to implement recommendations stemming from the workshop on Conditions (December 2016) when assessing orphan designation applications. COMP topic leader: Daniel O’ Connor Other Committee participants: Member/Alternate

Name

Member State

Member

Frauke Naumann-Winter

DE

Member

Ingeborg Barišić

HR

Member

Violeta Stoyanova-Beninska

NL

Member

Kerstin Westermark

Nominated by EC

Expert

Virginie Hivert

EURORDIS*

*Affiliation COMP work plan 2017 EMA/COMP/870730/2016

Page 3/6



Analysis of non-clinical models -

Publish the outcome of the analysis on non-clinical models initiated in 2016;

-

Decide on a new therapeutic area and initiate analysis of data from non-clinical models.

COMP topic leader: Bruno Sepodes Other Committee participants: Member/Alternate

Name

Member State

Member

Fernando Méndez Hermida

ES

Member

Melinda Sobor

HU

Member

Armando Magrelli

IT

Member

Michel Hoffmann

LU

Member

Robert Nistico

MT

Member

Violeta Stoyanova-Beninska

NL

Member

Dinah Duarte

PT

Member

Eva Malíková

SK

Member

Mario Ricciardi

Patients’ organisations

Member

Giuseppe Capovilla

Nominated by EC

Expert

Julian Isla

EURORDIS*

representative

*Affiliation



Establish a working group on prevalence to: -

Update the document “Points to Consider on the calculation and reporting of the prevalence of a condition for orphan designation” (COMP/436/01) and issue a publication on the subject;

-

Finalise a publication based on cases discussed by COMP;

-

Organise a workshop on calculation of prevalence for orphan designation and review of criteria for orphan designation at time of marketing authorisation.

COMP topic leader: Frauke Naumann-Winter Other Committee participants:



Member/Alternate

Name

Member State

Member

Vallo Tillmann

EE

Member

Geraldine O’Dea

IE

Member

Irena Rogovska

LV

Member

Giuseppe Capovilla

Nominated by EC

Discuss each protocol assistance question in the Protocol Assistance Working Group to prepare for in-depth discussions within the COMP plenary, with the aim of improving recommendations to sponsors for the demonstration of significant benefit taking into account the Commission’s Notice (2016/C 424/03) and principles identified by the working group on significant benefit when assessing criteria for orphan designation. COMP topic leader: Armando Magrelli Other Committee participants:

COMP work plan 2017 EMA/COMP/870730/2016

Page 4/6

Member/Alternate

Name

Member State

Chair

Bruno Sepodes

Member

Brigitte Blöchl-Daum

AT

Member

Kateřina Kopečková

CZ

Member

Frauke Naumann-Winter

DE

Member

FI

Member

Karri Penttila Dinko Vitezic

Member

Violeta Stoyanova-Beninska

NL

Member

Daniel O’Connor

UK

Member (Vice-chair)

Lesley Greene

Patients’ organisations

HR

representative Member

Kerstin Westermark

Nominated by EC

Expert

Virginie Hivert

EURORDIS*

Expert

Julian Isla

EURORDIS*

*Affiliation

2. Horizontal activities and other areas 2.1. Committees and Working Parties 2.1.1. Additional objectives and activities Key objectives •

Through PDCO-COMP interaction meetings, to further elaborate and develop the interaction process between the PDCO and COMP in view of appropriate consistency of opinions, exchange of expertise and effective use of incentives.



Improve the naming convention of ATMPs across Committees.



Make sure there is a common understanding across Committees on significant benefit when used for orphan designation and at maintenance.

Activities in 2017 •

Discuss in COMP-PDCO working group how to increase transparency on incentives from orphan and paediatric legislation and how to make a better use of data generated in PIPs to obtain incentives. COMP topic leader: Frauke Naumann-Winter Other Committee participants: Member/Alternate

Name

Member State

Member

Irena Bradinova

BG

Member

Armando Magrelli

IT

Member

Aušra Matulevičienė

LT

Member

Bożenna Dembowska-Bagińska

PL

Member

Mario Ricciardi

Patients’ organisations

Member

Kerstin Westermark

Nominated by EC

Member

Giuseppe Capovilla

Nominated by EC

representative

COMP work plan 2017 EMA/COMP/870730/2016

Page 5/6



Member/Alternate

Name

Member State

Member

Ingeborg Barišić

Nominated by EC

Explore the possibility to set up a COMP-CAT working group to improve the nomenclature classification system for orphan advance therapy medicinal products across Committees. COMP topic leader: Karri Penttila Other Committee participants:



Member/Alternate

Name

Member State

Member

Frauke Naumann-Winter

DE

Member

Fernando Méndez Hermida

ES

Member

Armando Magrelli

IT

Member

Ingrid Wang

NO

Contribute to the development of a regulatory analysis on the various provisions on significant benefit in the context of +1 year, paediatrics and orphans led by CHMP. COMP topic leader: Bruno Sepodes Other Committee participants: Member/Alternate

Name

Member State

Member

Frauke Naumann-Winter

DE

Member

Violeta Stoyanova-Beninska

NL

Member

Kerstin Westermark

Nominated by EC

Member

Mario Ricciardi

Patients’ organisations representative

2.2. International activities 2.2.1. Exchange of information Key objectives •

To further develop interactions with the Office of New Drugs, Centre for Drug Evaluation and Research at FDA to discuss post designation issues

Activities in 2017 •

Strengthen dialogue with FDA topics such as major contribution to patients’ care, prevalence, orphan similarity, incentives, and accessibility to patients. COMP topic leader: Bruno Sepodes Other Committee participants: Member/Alternate

Name

Member State

Member

Frauke Naumann-Winter

DE

Member

Dinah Duarte

PT

Member (Vice-chair)

Lesley Greene

Patients’ organisations representative

COMP work plan 2017 EMA/COMP/870730/2016

Page 6/6

COMP work plan 2017 - European Medicines Agency - Europa EU

Feb 15, 2017 - Improve the quality of initial orphan designation applications by ... Maintenance ... Development of strategies to implement recommendations ...

127KB Sizes 3 Downloads 244 Views

Recommend Documents

BSWP Work Plan 2017 - European Medicines Agency - Europa EU
Jan 26, 2017 - different aspects, or if these aspects call for the development of new ... Joint EMA Symposium in the margins of the CEN-ISBS conference, ...

CAT work plan 2017 - European Medicines Agency - Europa EU
Apr 12, 2017 - Member. Marc Turner. Scottish National Blood Transfusion. Service .... CAT will collaborate with the BWP and the HMA innovation network on this ... 1.3.3. Addressing the Environmental Risk assessment of ATMPs containing.

PDCO work plan 2017 - European Medicines Agency - Europa EU
Jan 27, 2017 - 30 Churchill Place ○ Canary Wharf ○ London E14 5EU ○ United Kingdom. An agency of the European Union. Telephone +44 (0)20 3660 .... best available scientific expertise in the Network and ensure that paediatric information related

RadDG Work plan 2017 - European Medicines Agency - Europa EU
Dec 15, 2016 - Work plan for the Radiopharmaceutical Drafting Group for. 2017. Chairperson: Anabel Cortes Blanco. Status of the work plan: Adopted in ...

Action plan - European Medicines Agency - Europa EU
5 days ago - Guidelines should include more details on the principles of good information design in which content and layout are ... relevance and importance of the QRD template is also acknowledged in this respect as it is the main tool .... databas

PRAC Work Plan 2018 - European Medicines Agency - Europa EU
Jan 31, 2018 - Activities in 2018. PRAC activities to achieve the objectives set for this area: •. Review of lessons learnt from the pilot regulatory network study involving EMA, Spain and the United Kingdom, as a source of learnings for regulatory

ONCWP Work plan 2018 - European Medicines Agency - Europa EU
Dec 14, 2017 - Send a question via our website www.ema.europa.eu/contact ... ad-hoc to respond to time-sensitive requests on products and to progress guidelines, as required. 2. Guidelines. 2.1. New EU Guidelines ... Recommendation to the CAT on data

July 2017 - European Medicines Agency - Europa EU
Jul 5, 2017 - Send a question via our website www.ema.europa.eu/contact ... non-proprietary names (INN) and therapeutic areas for all new ... also available in the monthly reports of the Committee for Orphan Medicinal Products (COMP).

September 2017 - European Medicines Agency - Europa EU
Oct 10, 2017 - 30 Churchill Place ○ Canary Wharf ○ London E14 5EU ○ United Kingdom. Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555. Send a question via our .... Art. 58 (WHO) scientific opinions. 1. 1. 1. 1. 0. 1. 1. 0. Opinions on

April 2017 - European Medicines Agency - Europa EU
May 8, 2017 - Information Management Division ... This document provides current information related to the volume and evaluation of .... Plasma master file.

HMPC work plan 2015 - European Medicines Agency - Europa EU
Jan 30, 2018 - HMPC work plan. EMA/HMPC/150152/2018. Page 2/7. Evaluation activities for herbal medicinal products as defined in Reg. (EC) No 726/2004 and Dir. 2001/83/EC. 1.1. Establishment and update of EU herbal monographs and list entries. Activi

January 2017 - European Medicines Agency - Europa EU
Feb 13, 2017 - Monthly report on application procedures, guidelines and .... of MRLs for new substances under article 3 of Regulation (EC) No 470/2009.

August 2017 - European Medicines Agency - Europa EU
Sep 11, 2017 - Pre-authorisation: Marketing-authorisation applications*. 2014. 2015 ... marketing authorisation. **. 4. 3. 7. 2 ... Plasma master file. (includes ...

July 2017 - European Medicines Agency - Europa EU
Aug 11, 2017 - 30 Churchill Place ○ Canary Wharf ○ London E14 5EU ○ United Kingdom. An agency of the European Union. Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 .... Art. 58 (WHO) scientific opinions. 1. 1. 1. 1. 0. 1. 1. 0. Opinions

Work programme 2017 - European Medicines Agency - Europa EU
Oct 9, 2017 - In 2017, an audit of the EU Portal and Database will take place and, on the basis of .... These frameworks collectively offer a platform for exchange and multi-stakeholder dialogue at the. European ...... EudraVigilance database and by

September 2017 - European Medicines Agency - Europa EU
Oct 13, 2017 - applications for initial evaluations, extensions, variations and renewals concerning marketing authorisations (MAs); ... Initial evaluation of marketing authorisation applications. 2014. 2015. 2016 .... Out of scope. 1 Establishment of

September 2017 - European Medicines Agency - Europa EU
Oct 13, 2017 - 2014. 2015. 2016. 2017. Scientific advice requests submitted and advice given. Submitted. Advice given .... Lokivetmab. •. Zoetis Belgium SA.

February 2017 - European Medicines Agency - Europa EU
Mar 16, 2017 - Information Management Division ... This document provides current information related to the volume and evaluation of .... Plasma master file.

August 2017 - European Medicines Agency - Europa EU
Sep 11, 2017 - Information Management Division. Monthly statistics report: .... (includes initial certification, variations and annual re-certification). 16. 16. 17. 19.

Work programme 2017 - European Medicines Agency - Europa EU
Oct 9, 2017 - possible expertise for the regulation of medicines in the European Union (EU). To deliver on its responsibilities, EMA works closely with the NCAs. This means the environment, trends, workload forecasts and implementation of a number of

Agenda - European Medicines Agency - Europa EU
Jul 7, 2017 - COMMUNITY MARKETING AUTHORISATIONS AND EXTENSIONS. 2.1. Opinions ... Quality. Rapp: E. Werner .... solutions table with EMA and CVMP responses to the recommendations made by the FishMed Plus. Coalition ...

May 2016 - European Medicines Agency - Europa EU
Jun 22, 2016 - Information Management Division ... This document provides current information related to the volume and evaluation of .... Plasma master file.

Eleclazine - European Medicines Agency - Europa EU
Feb 9, 2017 - Notification of discontinuation of a paediatric development which is covered by an agreed ... for the following reason(s): (tick all that apply).

July 2016 - European Medicines Agency - Europa EU
Jul 4, 2016 - Send a question via our website www.ema.europa.eu/contact ... non-proprietary names (INN) and therapeutic areas for all new ... also available in the monthly reports of the Committee for Orphan Medicinal Products (COMP).